Results 1 to 10 of about 10,633 (106)

A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors [PDF]

Molecules, 2020
The aim of the research was to assess the impact of O-1602—novel GPR55 and GPR18 agonist—in the rat model of detrusor overactivity (DO). Additionally, its effect on the level of specific biomarkers was examined. To stimulate DO, 0.75% retinyl
Andrzej Wróbel, Aleksandra Szopa, Anna Serefko, Ewa Poleszak   +3 more
doaj   +5 more sources

O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment [PDF]

Frontiers in Pharmacology, 2020
In view of the fact that GPR55 receptors are localized in brain areas implicated in the pathophysiology of depression, GPR55 gene expression is reduced in the dorsolateral prefrontal cortex of suicide victims, and GPR55 receptor agonism exerts an ...
Andrzej Wróbel, Anna Serefko, Aleksandra Szopa, Daniela Ulrich, Ewa Poleszak, Tomasz Rechberger   +5 more
doaj   +6 more sources

Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity [PDF]

Endocrine Connections, 2019
Atypical cannabinoid compounds O-1602 and O-1918 are ligands for the putative cannabinoid receptors G protein-coupled receptor 55 and G protein-coupled receptor 18.
Anna C Simcocks, Kayte A Jenkin, Lannie O’Keefe, Chrishan S Samuel, Michael L Mathai, Andrew J McAinch, Deanne H Hryciw   +6 more
doaj   +6 more sources

Antitumor Activity of Abnormal Cannabidiol and Its Analog O-1602 in Taxol-Resistant Preclinical Models of Breast Cancer [PDF]

Frontiers in Pharmacology, 2019
Cannabinoids exhibit anti-inflammatory and antitumorigenic properties. Contrary to most cannabinoids present in the Cannabis plant, some, such as O-1602 and abnormal cannabidiol, have no or only little affinity to the CB1 or CB2 cannabinoid receptors and
Andrea Tomko, Lauren O’Leary, Hilary Trask, John C. Achenbach, Steven R. Hall, Steven R. Hall, Kerry B. Goralski, Kerry B. Goralski, Lee D. Ellis, Denis J. Dupré   +9 more
doaj   +5 more sources

O-1602 Promotes Hepatic Steatosis through GPR55 and PI3 Kinase/Akt/SREBP-1c Signaling in Mice. [PDF]

Int J Mol Sci, 2021
Non-alcoholic fatty liver disease is recognized as the leading cause of chronic liver disease. Overnutrition and obesity are associated with hepatic steatosis. G protein-coupled receptor 55 (GPR55) has not been extensively studied in hepatic steatosis, although its endogenous ligands have been implicated in liver disease progression.
Kang S, Lee AY, Park SY, Liu KH, Im DS.
europepmc   +4 more sources

The Role of Atypical Cannabinoid Ligands O-1602 and O-1918 on Skeletal Muscle Homeostasis with a Focus on Obesity. [PDF]

Int J Mol Sci, 2020
O-1602 and O-1918 are atypical cannabinoid ligands for GPR55 and GPR18, which may be novel pharmaceuticals for the treatment of obesity by targeting energy homeostasis regulation in skeletal muscle. This study aimed to determine the effect of O-1602 or O-1918 on markers of oxidative capacity and fatty acid metabolism in the skeletal muscle.
Simcocks AC, O'Keefe L, Jenkin KA, Cornall LM, Grinfeld E, Mathai ML, Hryciw DH, McAinch AJ.   +7 more
europepmc   +5 more sources

The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. [PDF]

Inflamm Bowel Dis, 2011
Cannabinoids are known to reduce intestinal inflammation. Atypical cannabinoids produce pharmacological effects via unidentified targets. We were interested in whether the atypical cannabinoid O-1602, reportedly an agonist of the putative cannabinoid receptor GPR55, reduces disease severity of dextran sulfate sodium (DSS) and trinitrobenzene sulfonic ...
Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, Zimmer A, Lutz B, Mackie K, Bradshaw HB, McCafferty DM, Sharkey KA, Storr M.   +12 more
europepmc   +4 more sources

O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms. [PDF]

J Mol Med (Berl), 2013
Cannabinoids have antiinflammatory and antitumorigenic properties. Some cannabinoids, such as O-1602, have no or only little affinity to classical cannabinoid receptors but exert cannabinoid-like antiinflammatory effects during experimental colitis. Here, we investigated whether O-1602 shows antitumorigenic effects in colon cancer cells and whether it ...
Kargl J, Haybaeck J, Stančić A, Andersen L, Marsche G, Heinemann A, Schicho R.   +6 more
europepmc   +4 more sources

A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.

Neuropharmacology, 2013
The G protein-coupled receptor 55 (GPR55) is a novel cannabinoid (CB) receptor, whose role in the gastrointestinal (GI) tract remains unknown. Here we studied the significance of GPR55 in the regulation of GI motility.GPR55 mRNA and protein expression were measured by RT-PCR and immunohistochemistry.
Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A, Göke B, Sharkey KA, Storr M.   +10 more
europepmc   +4 more sources

Activating GPR55 protects cochlear hair cells against cisplatin-induced ototoxicity via inhibiting MAPK pathway [PDF]

Scientific Reports
Cisplatin (CDDP) is an effective chemotherapeutic agent used to treat solid tumors, but it can cause irreversible hearing loss. Currently, there are no specific preventive measures available for this side effect.
Lingna Guo, Ruitang Wang, Yatang Wang, Houqiang Ruan, Yuhua Zhang, Yongjie Wei, Jiawei Du, Qiaojun Fang, Jianming Yang, Wei Cao   +9 more
doaj   +2 more sources